ClinicalTrials.gg
CompletedNCT00527111Updated Nov 3, 2016Results posted

Pre-op Rectal ChemoRad +/- Cetuximab

A Phase 2 interventional study of Cetuximab and 5-fluorouracil in Rectal Cancer, sponsored by US Oncology Research. Completed at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
139
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing cetuximab in Rectal Neoplasms — 4 open to participants now, 8 under way, 3 of them phase 3. Cetuximab · Rectal Neoplasms.

Enrollment
13th of 58
139 · median 50
Started
2007
with 11 others
Phase 2
38 of 60
1 open now
Registered
28th of 60
by date

Among the 60 studies testing cetuximab in Rectal Neoplasms, this one is the 13th largest by enrollment of the 58 interventional ones that give a count, is one of 12 that started in 2007, is one of 38 in phase 2, and was the 28th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

4 of the 60 studies testing cetuximab in Rectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 405 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing cetuximab in Rectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.

Read the detailed description

Rectal cancer remains a significant cause of morbidity and mortality in the United States. Standard treatment for patients with locally advanced rectal cancer generally includes combined chemotherapy and radiotherapy administered either before (neoadjuvant) or after (adjuvant) definitive surgical resection. Published data from Germany has suggested advantages to a neoadjuvant strategy. Currently, the standard concurrent chemoradiotherapy regimen in the United States is pelvic irradiation administered concurrently with 5-fluorouracil (5-FU) given as a protracted venous infusion. However, local recurrence remains a problem. Recently completed randomized trials of chemoradiotherapy have demonstrated local recurrence rates between 8-17% even with currently accepted standard chemoradiotherapy and adequate surgical management.

Several recent trials have explored the use of radiotherapy and cetuximab with good results.

Because of the non-overlapping toxicity profiles and the potentially diverse and complimentary mechanisms of action, the combination of chemotherapy plus ERBITUX given concurrently with pelvic radiotherapy may improve on the outcomes seen with current standards for patients with locally advanced adenocarcinoma of the rectum.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Note: Please see Section 8.1 for the necessary "Prestudy Assessments".

A patient will be eligible for inclusion in this study if s/he meets all of the following criteria:

  • Has a confirmed diagnosis of newly diagnosed adenocarcinoma of the rectum (tumor within 15 cm of the anal verge). Location of tumor (lower 1/3rd vs. middle or upper 1/3rd) and pre-treatment nodal status (N0 vs. N1 or N2) will be recorded in the eCRF. Patients with only non- are eligible as long as they meet the other disease requirements in this criterion as well as all other eligibility criteria.
  • Has tumor that is locally advanced (T3/T4 or lymph node positive) by preoperative assessment with CT or MRI imaging or transrectal ultrasonography.
  • Has no evidence of distant by radiographic staging
  • Has an Performance Status (PS) 0-1
  • Is greater than 18 years of age
  • Has adequate marrow and organ system function as assessed by the following lab values:

White blood cell (WBC) count See protocol for specific details (ANC) See protocol for specific details See protocol for specific details Total See protocol for specific details and ALT See protocol for specific details Serum creatinine See protocol for specific details count See protocol for specific details

  • Sexually active women of must use an effective method of during the course of the study, in a manner such that risk of failure is minimized.

Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy. In addition, men enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth control.

All WOCBP MUST have a negative pregnancy test within 3 weeks prior to registration (confirmed within 7 days prior to first receiving product). If the pregnancy test is positive, the patient must not receive investigational product and must not be enrolled in the study.

In addition, all WOCBP should be instructed to contact the Investigator immediately if they suspect they might be pregnant (eg, missed or late menstrual period) at any time during study participation.

The Investigator must immediately notify BMS in the event of a confirmed pregnancy in a patient participating in the study.

  • Has signed a Patient Form
  • Has signed a Patient Authorization Form

Exclusion criteria

Exclusion Criteria:

  • A patient will be excluded from this study if s/he meets any of the following criteria:
  • Has another disease similar to one being studied (ie, colon cancer)
  • Has evidence of distant by radiographic staging
  • Has had prior treatment for the current disease
  • Has had prior stem cell or bone marrow transplant or any organ transplant with the exception of corneal transplant or cadaver bone graft
  • Has a history of to any of study treatments
  • Has had a prior severe infusion reaction to a monoclonal antibody
  • Has received prior therapy, at any time, which specifically and directly targets the EGFR pathway
  • Has a significant history of uncontrolled cardiac disease; ie, uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, or cardiomyopathy with decreased
  • Has evidence of CNS involvement (CNS imaging is not required for study enrollment unless clinically suspected CNS disease is present.)
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection or Gilbert's Syndrome
  • Has a history of other within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs. Patients, who have received prior radiotherapy to any regional site other than the pelvis, as long as all other inclusion criteria are met, could be considered for enrollment after discussion with Dr. McCollum.
  • Is a pregnant or nursing woman
  • Is unable to comply with requirements of study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Chemoradiotherapy plus Cetuximab

    Pelvic irradiation plus 5-fluorouracil plus cetuximab

    Drug: Cetuximab · Drug: 5-fluorouracil · Radiation: Pelvic irradiation

  • Active comparator
    Chemoradiotherapy alone

    Pelvic irradiation plus 5-fluorouracil

    Drug: 5-fluorouracil · Radiation: Pelvic irradiation

Interventions

  • Also known as: Erbitux

  • Also known as: 5-FU

  • RadiationPelvic irradiation

    Also known as: Radiotherapy

06

What researchers measure

Primary outcomes

  1. Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.

    A pathologic complete response (pCR) is defined as no pathologic evidence of invasive disease at the primary site in the bowel wall or in examined mesorectal tissue and/or lymph nodes.

    Time frame: 5 years

Secondary outcomes

  1. To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.

    Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: 5 years

  2. 5- Year Overall Survival (OS) Rate

    Overall survival is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.

    Time frame: 5 years

  3. Recurrence-free Survival (RFS) Rate at 5 Years

    RFS is measured from the date of randomization to the date of first documented disease recurrence or date of death, whichever comes first. If a patient neither recurrences nor dies, this patient will be censored at the date of last contact.

    Time frame: 5 years

  4. KRAS Mutation Rate

    Percentage of Participants with KRAS mutation.

    Time frame: 5 years

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
Started7069
Completed5047
Not completed2022
Withdrew: Adverse event1413
Withdrew: Death01
Withdrew: Investigator request21
Withdrew: Patient request25
Withdrew: Other22

Outcome measures

PrimaryPercentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.

A pathologic complete response (pCR) is defined as no pathologic evidence of invasive disease at the primary site in the bowel wall or in examined mesorectal tissue and/or lymph nodes.

Time frame:
5 years
Reported as:
Number · percentage of participants
Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.
percentage of participantsChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
Percentage of Pathologic Response Rate (pCR) With 95% Confidence Interval.26.6 (16.3 to 39.1)26.7 (16.1 to 39.7)
SecondaryTo Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.

Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
5 years
Reported as:
Number · percentage of participants
To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.
percentage of participantsChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
To Determine Objective Response Rate (ORR) Based on RECIST Local Recurrence-free Survival in These Patient Groups; Overall and Recurrence-free Survival in These Cohorts.52.2 (39.7 to 64.6)43.5 (31.0 to 56.7)
Secondary5- Year Overall Survival (OS) Rate

Overall survival is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the date of last contact.

Time frame:
5 years
Reported as:
Number · probability of overall survival
5- Year Overall Survival (OS) Rate
probability of overall survivalChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
5- Year Overall Survival (OS) Rate0.81 (0.69 to 0.89)0.68 (0.53 to 0.79)
SecondaryRecurrence-free Survival (RFS) Rate at 5 Years

RFS is measured from the date of randomization to the date of first documented disease recurrence or date of death, whichever comes first. If a patient neither recurrences nor dies, this patient will be censored at the date of last contact.

Time frame:
5 years
Reported as:
Number · probability of recurrence-free survival
Recurrence-free Survival (RFS) Rate at 5 Years
probability of recurrence-free survivalChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
Recurrence-free Survival (RFS) Rate at 5 Years0.65 (0.51 to 0.76)0.585 (0.44 to 0.71)
SecondaryKRAS Mutation Rate

Percentage of Participants with KRAS mutation.

Time frame:
5 years
Reported as:
Number · percentage of participants with mutation
KRAS Mutation Rate
percentage of participants with mutationChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
KRAS Mutation Rate32.544.0

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Chemoradiotherapy Plus Cetuximab—10/67 (14.9%)61/67 (91%)
Chemoradiotherapy Alone—5/62 (8.1%)47/62 (75.8%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
DEHYDRATIONGastrointestinal disorders5/672/62
DIARRHEAGastrointestinal disorders5/671/62
MUCOSITISInfections and infestations1/672/62
SEPSISInfections and infestations2/670/62
ABDOMINAL PAINGastrointestinal disorders1/671/62
ENTERITISGastrointestinal disorders0/671/62
SWALLOWING PAINFULGastrointestinal disorders0/671/62
WEAKNESS GENERALIZEDGeneral disorders0/671/62
COLITISGastrointestinal disorders1/670/62
FEVERGeneral disorders1/670/62
Most frequent other events
Showing 10 of 25
Most frequent other events
EventChemoradiotherapy Plus CetuximabChemoradiotherapy Alone
RASHSkin and subcutaneous tissue disorders50/675/62
DIARRHEAGastrointestinal disorders36/6733/62
WEAKNESSGeneral disorders25/6719/62
MUCOSITISInfections and infestations19/6712/62
NAUSEAGastrointestinal disorders18/6713/62
ANOREXIAGastrointestinal disorders16/6713/62
HEADACHEGeneral disorders13/671/62
HYPOMAGNESAEMIAMetabolism and nutrition disorders10/674/62
HAND-FOOT SYNDROMESkin and subcutaneous tissue disorders2/679/62
ABDOMINAL PAINGastrointestinal disorders5/678/62

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)Chemoradiotherapy Plus CetuximabChemoradiotherapy AloneTotal
Mean55.9 ± 11.061.4 ± 11.758.6 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Chemoradiotherapy Plus CetuximabChemoradiotherapy AloneTotal
Female262147
Male444892
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Chemoradiotherapy Plus CetuximabChemoradiotherapy AloneTotal
Caucasian5960119
Black8412
Hispanic134
Asian213
Other011
Region of Enrollment
Region of Enrollment(participants)Chemoradiotherapy Plus CetuximabChemoradiotherapy AloneTotal
United States7069139
08

Study locations

41 sites
  • Oncology Associates D.B.A. Hematology Oncology Physicians & Extenders
    Tucson, Arizona 85704, United States
  • Melbourne Internal Medicine Associates
    Melbourne, Florida 32901, United States
  • Advanced Medical Specialties
    Miami, Florida 33133, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Cancer Care & Hematology Specialists of Chicagoland, PC
    Niles, Illinois 60714, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 76227, United States
  • Kansas City Cancer Centers-Southwest
    Overland Park, Kansas 66210, United States
  • Alliance Hematology Oncology PA
    Westminster, Maryland 21157, United States
  • Missouri Cance Associates
    Columbia, Missouri 65201, United States
  • St. Joseph Oncology, Inc.
    St. Joseph, Missouri 64507, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • Cancer Centers of North Carolina
    Raleigh, North Carolina 27607, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401, United States
  • Texas Oncology - Amarillo
    Amarillo, Texas 79106, United States
  • Texas Oncology Cance Center
    Austin, Texas 78731, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Methodist Charlton Cancer Ctr.
    Dallas, Texas 75237, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Cancer Center
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr
    El Paso, Texas 79915, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • Lake Vista Cancer Center
    Lewisville, Texas 75067, United States
  • Longview Cance Center
    Longview, Texas 75601, United States
  • Allison Cancer Center
    Midland, Texas 79701, United States
  • Texas Oncology-Odessa
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • HOAST - Medical Dr.
    San Antonio, Texas 78229, United States
  • Texas Cancer Center - Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology Cancer Center-Sugar Land
    Sugar Land, Texas 77479, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology Cancer Care and Research
    Waco, Texas 76712, United States
  • Texas Oncology, P.A.
    Webster, Texas 77598, United States
  • Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Highline Medical Oncology
    Burien, Washington 98166, United States
  • Cancer Care Northwest-South
    Spokane, Washington 99202, United States
  • Northwest Cancer Specialists-Vancouver
    Vancouver, Washington 98684, United States
  • Yakima Valley Mem Hosp/North Star Lodge
    Yakima, Washington 98902, United States
  • Raleigh Regional Cancer Center
    Beckley, West Virginia 25801, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2007
First posted
Sep 10, 2007
Start
Feb 2007
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00527111
Responsible party
Sponsor
First posted
Sep 10, 2007
Start date
Feb 2007
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Andrew D McCollum, MD
principal investigator · US Oncology Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion